On November 11, 2020, Inipharm announced the close of a $35 million Series A financing round. Founded in 2018, the company is focused on discovering and developing therapies for liver and related diseases, with its initial program focused on those associated with the genetically defined target HSD17B13. The Series A funding will support the advancement of Inipharm’s lead program through IND filing and into clinical trials. 5AM Ventures and Wu Capital joined existing investors Frazier Healthcare Partners and Jubilant Biosys Limited in the round.

The Wilson Sonsini Goodrich & Rosati team that represented Inipharm on IP matters related to the transaction includes Michael Hostetler, Uale Taotafa, and Céline Bonnefous. Wilson Sonsini has represented the company in patent matters since the company’s inception.

For more information, please see Inipharm’s press release.